NCT03702660 (GA-7) is a NA clinical trial of GIP(3-30)NH2 in Type2 Diabetes, sponsored by University Hospital, Gentofte, Copenhagen.

Who is sponsoring NCT03702660?

NCT03702660 is sponsored by University Hospital, Gentofte, Copenhagen.

What drugs are being tested in NCT03702660?

Interventions in NCT03702660: GIP(3-30)NH2, Peripheral venous cannulation, GLP-1.

What condition does NCT03702660 study?

NCT03702660 studies Type2 Diabetes.

Is NCT03702660 still recruiting?

NCT03702660 is currently completed. Last updated 27 April 2021.

Last reviewed 2021-04-27 · How we verify

NCT03702660: GA-7

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of GIP After a Meal in Patients With Type 2 Diabetes

Completed NA Last updated 27 April 2021

What this trial tests

NA trial testing GIP(3-30)NH2 in Type2 Diabetes in 10 participants. Completed in 23 January 2018.

Timeline

1 August 2017

Primary endpoint
23 January 2018

23 January 2018

Quick facts

Lead sponsor	University Hospital, Gentofte, Copenhagen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	10
Start date	1 August 2017
Primary completion	23 January 2018
Estimated completion	23 January 2018
Sites	1 location across Denmark

Drugs / interventions tested

GIP(3-30)NH2
Peripheral venous cannulation
GLP-1 — full drug profile →

Conditions studied

Type2 Diabetes — all drugs for Type2 Diabetes →

Sponsor

University Hospital, Gentofte, Copenhagen

Who can join

Adults 18 to 75, male only, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the effects of antagonising GIP after a meal on plasma levels of glucagon. 10 participants are going through four experimental days each, where they ingest a meal and afterwards receive infusions of either GIP receptor antagonist, GLP-1, GIP receptor antagonist + GLP-1 or placebo (saline) in a randomised order. The primary endpoint of the study is plasma levels of glucagon, which we hypothesize will decrease with infusion of GIP receptor antagonist and/or with infusion of GLP-1.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

58<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : Stockholm, Sweden, 19 - 23 September 2022.
· 2022 · cited 6× · PMID 35920845 · DOI 10.1007/s00125-022-05755-w

Verify or expand the search:

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting

Other University Hospital, Gentofte, Copenhagen trials

Trials by the same sponsor.

NCT07171723 — Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment · Phase 1, PHASE2 · recruiting
NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
NCT06845033 — Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity · NA · not yet recruiting
NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03702660 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
Last refreshed: 27 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03702660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing